In the BioHarmony Drug Report Database
Adapalene
Differin (adapalene) is a small molecule pharmaceutical. Adapalene was first approved as Differin on 1996-05-31. It is used to treat acne vulgaris in the USA. The pharmaceutical is active against retinoic acid receptor beta and retinoic acid receptor gamma. In addition, it is known to target retinoic acid receptor alpha. Epiduo’s patents are valid until 2028-05-31 (FDA).
Trade Name
|
Differin |
|---|---|
Common Name
|
adapalene |
ChEMBL ID
|
CHEMBL1265 |
Indication
|
acne vulgaris |
Drug Class
|
Retinoids |
Image (chem structure or protein)